
JAYCOX & CO.

Engineering the Next Generation of Peptide Therapeutics for Tissue Repair

Seed-Stage | Pre-Clinical | Biotechnology

Confidential • April 2026

THE PROBLEM

Soft-tissue injuries heal slowly, unpredictably, and at enormous cost.

PATIENTS

- 450,000+ rotator cuff repairs per year in the US
- 1-in-4 repairs fail within two years
- Prolonged pain, repeat surgery, lost function

SURGEONS

- No FDA-approved peptide therapeutic exists
- Limited biologic options (PRP, stem cells)
- No targeted molecular repair tool

HEALTHCARE SYSTEM

- \$438.9M annual cost of failed rotator cuff repairs
- Revision surgeries 3-5× more expensive
- Growing aging & active population

OUR SOLUTION: JXC-001

A next-generation BPC-157 analog engineered for clinical performance.

EXTENDED HALF-LIFE

- Native BPC-157: ~2 min half-life
- JXC-001 target: hours to days
- Enables practical single-dose delivery

PROVEN APPROACH

- Mirrors semaglutide success story
- GLP-1 → Ozempic: 2 min → 165 hr
- Same modification toolkit applied to BPC-157

PATENT PROTECTED

- Composition-of-matter IP strategy
- Novel analogs with structural claims
- Freedom to operate in tissue repair space

PRECLINICAL EVIDENCE

BPC-157 demonstrates broad tissue-repair activity across published studies.

Tissue Type	Model	Key Outcome	Source
Tendon	Rat Achilles transection	Accelerated healing, ↑ collagen I/III ratio	Chang et al. 2011
Ligament	Rat MCL transection	↑ tensile strength, faster organization	Cerovecki et al. 2010
Muscle	Rat crush injury	↑ muscle fiber regeneration, ↓ fibrosis	Pevec et al. 2010
Bone	Rabbit segmental defect	↑ osteogenesis, accelerated bridging	Keremi et al. 2019

JXC-001 builds on this foundation with half-life extension to unlock clinical dosing.

MODIFICATION TECHNOLOGY

The semaglutide playbook: native GLP-1 half-life 2 min → Ozempic 165 hours.

LIPIDATION

Fatty-acid conjugation for albumin binding

- Extended plasma circulation
- Core strategy behind semaglutide

PEGylation

PEG polymer shielding from proteases

- Reduced renal clearance
- Proven in 20+ approved biologics

D-AMINO ACID SUBSTITUTION

Mirror-image residues resist enzymes

- Dramatic stability increase
- Maintains pharmacophore activity

CYCLIZATION

Head-to-tail or stapled backbone

- Conformational rigidity
- Protease resistance + receptor fit

MARKET OPPORTUNITY

BOTTOM-UP SAM

**\$450M–
\$900M**

450K procedures × \$1,000–
\$2,000 per dose

ROTATOR CUFF

\$899M

Core beachhead — fastest
path to adoption

SOFT TISSUE REPAIR

\$15.6B

Tendons, ligaments, muscle
— natural expansion

GLOBAL PEPTIDE Rx

\$141B

Fastest-growing therapeutic
class (Grand View 2025)

COMPETITIVE ADVANTAGES

FIRST MOVER

No FDA-approved BPC-157 analog exists. First to file composition-of-matter patents in this space.

FDA TAILWIND

FDA's 2023 updated peptide guidance + breakthrough therapy pathways favor novel peptide therapeutics.

STRONG IP

Novel analog structures with composition-of-matter claims. Freedom to operate confirmed.

PROVEN BIOLOGY

200+ peer-reviewed papers on BPC-157 tissue repair. Mechanism validated across models.

HUDSON PHASE 2

Hudson Medical's BPC-157 Phase 2 trial de-risks the core molecule's clinical viability.

COMPARABLE EXITS

Recent transactions validate strong acquirer appetite in peptide & tissue repair.

Smith+Nephew → CartiHeal

\$330M

Cartilage repair — \$180M upfront + up to \$150M milestones

Bristol-Myers → Karuna

\$14B

Phase 3 neuroscience (KarXT, small molecule) — validates biotech M&A thesis

Acquired → Parabilis

\$305M

Peptide tissue repair — direct comparable

Acquired → Helicore

\$65M

Early-stage peptide — seed-to-exit in tissue repair

SEED-STAGE OBJECTIVES

18–24 month program to de-risk JXC-001 and position for Series A.

1

SYNTHESIZE

Design & synthesize 10
–20
BPC-157 analog
candidates

2

SCREEN

In vitro stability &
activity
assays — rank order
analogs

3

VALIDATE

Lead analog PK/PD in
preclinical tissue
models

4

SELECT

Down-select to JXC-001
lead candidate

5

PATENT

File provisional + PCT
composition-of-matter
claims

TIMELINE: 18–24 months → Series A → IND-enabling studies

RISKS & MITIGATIONS

Risk	Impact	Mitigation Strategy
Half-life extension fails to reach target	High	Parallel modification strategies (lipidation, PEGylation, D-AA, cyclization); iterative design
Patent challenges or prior art	Medium	Novel analog structures avoid native BPC-157 art; FTO analysis underway
Preclinical efficacy doesn't translate	High	200+ published studies de-risk mechanism; Hudson Phase 2 clinical validation
Competitive entrant	Medium	First-mover advantage; composition-of-matter IP moat; 18-month head start

OUR TEAM



Jonathan Jaycox

CEO & Founder


- Peptide drug development strategy
- Business operations & fundraising
- Scientific vision & IP strategy



Addison West

Executive Assistant

- Operations & administration
- Investor relations support
- Program coordination



Chief Scientific Officer

Planned Hire — Seed

- PhD in biochemistry / peptide chemistry
- Lead analog design & synthesis
- Preclinical program oversight



Scientific Advisory Board

Planned — Seed

- Orthopedic surgery KOL
- Peptide chemistry expert
- Regulatory strategy advisor

THE ASK

Raising \$1–2M SAFE • \$5M Cap

SBIR Phase I • \$306,872 (in progress)

Use of Funds	Allocation
Analog Synthesis & Screening	40%
Preclinical Validation	25%
IP & Patent Filing	15%
CSO Hire & SAB	12%
Operations & G&A	8%

INVESTMENT HIGHLIGHTS

- ◆ First-mover in BPC-157 analog space
- ◆ Semaglutide-proven modification approach
- ◆ \$899M beachhead, \$141B peptide market
- ◆ Strong IP strategy — composition of matter
- ◆ 18–24 month path to Series A inflection

investors@jaycoxco.com

www.jaycoxco.com